HPV16 E6 seropositivity among cancer-free men with oral, anal or genital HPV16 infection

Daniel C. Beachler, Tim Waterboer, Christine M. Pierce Campbell, Donna J. Ingles, Krystle A. Lang Kuhs, Alan G. Nyitray, Allan Hildesheim, Michael Pawlita, Aimée R. Kreimer, Anna R. Giuliano

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


Antibodies against the Human papillomavirus 16 (HPV16) E6 oncoprotein appear years prior to clinical diagnosis of anal and oropharyngeal cancer, but whether they develop around the time of HPV infection is unclear. Serum samples from 173 cancer-free men from the Human Papillomavirus Infection in Men (HIM) Study were tested for HPV antibodies and DNA. HPV16 E6 seropositivity was low among men with oral HPV16-infection (1/28; 3.6%, 95%CI=0.0–18.4%), anal HPV16-infection (1/61; 1.6%, 95%CI=0.0–8.8%), and 24-month persistent genital HPV16-infection (1/84; 1.2%, 0.0–6.5%). This suggests E6 seroconversion may not occur around the time of oral, anal, or genital HPV16 acquisition.

Original languageEnglish
Pages (from-to)141-144
Number of pages4
JournalPapillomavirus Research
StatePublished - Dec 1 2016

Bibliographical note

Publisher Copyright:
© 2016


  • Anal cancer
  • HPV
  • HPV16 E6 seropositivity
  • Oropharyngeal cancer
  • Penile cancer

ASJC Scopus subject areas

  • Virology
  • Infectious Diseases


Dive into the research topics of 'HPV16 E6 seropositivity among cancer-free men with oral, anal or genital HPV16 infection'. Together they form a unique fingerprint.

Cite this